ZAMBON, Alfonso
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.205
EU - Europa 5.693
AS - Asia 5.475
SA - Sud America 784
AF - Africa 142
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 23.314
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.942
SG - Singapore 1.697
IT - Italia 1.632
CN - Cina 1.249
GB - Regno Unito 1.097
HK - Hong Kong 971
DE - Germania 793
SE - Svezia 644
BR - Brasile 591
VN - Vietnam 567
PL - Polonia 278
BD - Bangladesh 257
FR - Francia 242
RU - Federazione Russa 222
FI - Finlandia 198
UA - Ucraina 164
KR - Corea 161
CA - Canada 140
IN - India 124
ID - Indonesia 93
BG - Bulgaria 77
NL - Olanda 76
TR - Turchia 71
MX - Messico 70
AR - Argentina 57
IE - Irlanda 47
ES - Italia 43
JP - Giappone 43
EC - Ecuador 39
BE - Belgio 37
IQ - Iraq 35
CO - Colombia 33
ZA - Sudafrica 33
MA - Marocco 31
AT - Austria 29
MY - Malesia 29
AE - Emirati Arabi Uniti 23
VE - Venezuela 23
PK - Pakistan 21
IR - Iran 18
CH - Svizzera 16
DZ - Algeria 15
EG - Egitto 15
TH - Thailandia 15
LT - Lituania 14
CL - Cile 13
RO - Romania 13
UZ - Uzbekistan 13
KE - Kenya 12
PH - Filippine 12
TN - Tunisia 12
CZ - Repubblica Ceca 11
PY - Paraguay 11
SA - Arabia Saudita 10
AU - Australia 8
CR - Costa Rica 8
IL - Israele 8
PE - Perù 8
PT - Portogallo 8
BY - Bielorussia 7
DO - Repubblica Dominicana 7
GE - Georgia 7
JM - Giamaica 7
JO - Giordania 7
HU - Ungheria 6
RS - Serbia 6
TT - Trinidad e Tobago 6
AZ - Azerbaigian 5
DK - Danimarca 5
ET - Etiopia 5
KZ - Kazakistan 5
LK - Sri Lanka 5
NP - Nepal 5
AL - Albania 4
BO - Bolivia 4
LB - Libano 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
AO - Angola 3
BZ - Belize 3
EE - Estonia 3
GT - Guatemala 3
HN - Honduras 3
KG - Kirghizistan 3
LU - Lussemburgo 3
OM - Oman 3
PA - Panama 3
SC - Seychelles 3
SV - El Salvador 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BH - Bahrain 2
BS - Bahamas 2
CY - Cipro 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
LV - Lettonia 2
MK - Macedonia 2
Totale 23.279
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.135
Singapore 1.108
Fairfield 1.030
Ashburn 1.023
Hong Kong 946
Woodbridge 629
Southend 576
Chandler 568
Houston 496
Modena 484
San Jose 466
Ann Arbor 439
Nyköping 384
Seattle 382
Cambridge 376
Hefei 372
Frankfurt am Main 350
Wilmington 328
London 294
Warsaw 256
Beijing 253
Jacksonville 227
Dearborn 222
Council Bluffs 205
Los Angeles 195
Ho Chi Minh City 191
Helsinki 176
Chicago 159
Dallas 158
The Dalles 148
Hanoi 145
Seoul 140
New York 131
Berlin 106
Bologna 95
San Diego 87
Princeton 75
Reggio Emilia 74
Sofia 74
Bremen 73
Milan 69
Boardman 67
Eugene 65
Lauterbourg 65
Jakarta 63
Buffalo 62
Moscow 60
Salt Lake City 58
Orem 52
São Paulo 49
Munich 46
Dublin 42
Shanghai 40
Parma 34
Redondo Beach 34
Rome 34
Formigine 33
Brussels 32
Amsterdam 31
Izmir 31
Redwood City 31
Tokyo 31
Atlanta 30
Da Nang 30
Toronto 30
Montreal 29
Tampa 27
Chennai 24
Stockholm 24
Denver 23
Vancouver 22
Wimbledon 22
Bomporto 21
Kent 21
Rio de Janeiro 21
Brooklyn 20
Elk Grove Village 20
Newark 20
Turin 20
Falls Church 19
Norwalk 19
Phoenix 19
Mexico City 17
Nuremberg 17
Voghera 17
Belo Horizonte 16
Des Moines 16
Johannesburg 16
Lappeenranta 16
Florence 15
Guangzhou 15
Haiphong 15
Madrid 15
Paris 15
Columbus 14
Manchester 14
Guayaquil 13
Ottawa 13
Poplar 13
Tashkent 13
Totale 16.336
Salva come PNG Salva come JPEG
Nome #
1 - ( 5 - TERT - BUTYL - 2 - ARYL - PYRAZOL - 3 - YL ) . 3 - 12 - FLUORO - 4 - [ ( 3 - OXO - 4H - PYRIDO [ 2 . 3 - BJPYRAZIN - 8 - YL ) OXY | PHENYLJUREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER 984
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships 597
Chiral polycyclic ketones via desymmetrization of dihaloolefins 446
Potential of wickerhamomyces anomalus in glycerol valorization 436
Cytocompatibility of potential bioactive cerium-doped glasses based on 45S5 392
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma 373
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling 366
Nucleoside 2’,3’-cyclic monophosphates in Aphanizomenon flos-aquae detected through nuclear magnetic resonance and mass spectrometry 348
A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors 343
A novel mechanism for the fluxional behaviour of [Pd(η2-tetramethylethylenetetracarboxylate)(2-methylthiomethylpyridine)] 341
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF 331
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 329
Cerium Containing Bioactive Glasses: A Review 328
Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations 324
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring 323
BRAF as a therapeutic target: A patent review (2006-2012) 319
Mesoporous bioactive glasses doped with cerium: Investigation over enzymatic-like mimetic activities and bioactivity 318
Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): Increasing cellular potency through optimization of a distal heteroaromatic group 312
Assessment of chloroaniline toxicity by the submitochondrial particle assay 311
Structure Model and Toxicity of the Product of Biodissolution of Chrysotile Asbestos in the Lungs 308
Boosting sunscreen stability: New hybrid materials from UV filters encapsulation 306
Investigation on the antimicrobial properties of cerium-doped bioactive glasses 304
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors 300
β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics 292
The discovery of novel, highly potent inhibitors of BRAF 282
Ce-MBGs Loaded with Gentamicin: Characterization and In Vitro Evaluation 280
Development and exploitation of CK2 inhibitors 280
1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy 275
Synthesis and evaluation of new chiral diols based on the dicyclopentadiene skeleton 274
Thiophene based A-D-A small molecules with a dithienosilole core: synthesis, theoretical calculations and optoelectronic properties 273
Tris-annelated benzenes selectively perfunctionalized on one side only: Hexachlorobenzotrinorbornadiene as a versatile scaffold for the construction of molecular domes 259
Non canonical Cyclic Nucleotides Monophosphates in Aphanizomenon flosaquae: nuclear magnetic resonance and mass spectrometry 258
Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring 256
"Hexacarboxytrindanes": Benzene rings with homotopic faces as scaffolds for the construction of D3 chiral architectures 253
Bifunctional mesoporous glasses for bone tissue engineering: Biological effects of doping with cerium and polyphenols in 2D and 3D in vitro models 251
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 250
Study on the toxicity of phenolic and phenoxy herbicides using the submitochondrial particle assay 248
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents 247
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors 244
Substituted aniline interaction with submitochondrial particles and quantitative structure-activity relationships 241
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds 240
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) 239
Efficient access to 5-substituted thiazoles by a novel metallotropic rearrangement 237
Surface acidity modifications induced by thermal treatments and acid leaching on microcrystalline H-BEA zeolite. A FTIR, XRD and MAS-NMR study 235
Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor–Induced Cutaneous Squamous Cell Carcinoma 234
1-(5-TERT-BUTYL-2-ARYL-PYRAZOL-3-YL)-3-2-FLUORO-4-(3-OXO-4H-PYRIDO2,3-BPYRAZIN-8-YL)OXYPHENYLUREA DERIVATIVES AS RAF INHIBITORS FOR THE TREATMENT OF CANCER 234
Internal motions in a fulleropyrrolidine tertiary amide with axial chirality 233
Gatekeeper mutations mediate resistance to BRAF-targeted therapies 232
Synthesis of the syn and anti isomer of 1,4,5,8,9,12-hexahydro-2,3,6,7,10,11-hexamethylidene-1,4 : 5,8 : 9,12-trimethanotriphenylene and Diels-Alder reactivity of the syn isomer 232
Isolation and characterization of all eight bisadducts of fulleropyrrolidine derivatives 228
Loading with Biomolecules Modulates the Antioxidant Activity of Cerium-Doped Bioactive Glasses 228
Novel oligothiophenes with reduced HOMO-LUMO band gap for Optoelectonics 227
Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives 223
Small molecule inhibitors of BRAF in clinical trials 220
ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF 220
Nucleophilic reactions at the ring carbons of thiiranium and thiirenium ions. An experimental and theoretical comparison of the S(N)2 and S(N)2-Vin mechanisms 217
Efficient cyclotrimerization of bicyclic vic-bromostannylalkenes promoted by copper(I) thiophen-2-carboxylate 216
Dual Kinase Targeting in Leukemia 216
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma 206
ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF 204
Expedient Access to Type II Kinase Inhibitor Chemotypes by Microwave-Assisted Suzuki Coupling 204
Qualitative and quantitative discrimination of fake and true alkene rotation processes in pd(η2-olefin) complexes. A new bimolecular mechanism 202
Cytocompatibility of mesoporous bioactive glasses doped with cerium and loaded with polyphenols 198
Evaluation of the Properties of Bioactive Mesoporous Glasses Doped with Cerium and Loaded with Polyphenols 195
Non-canonical Cyclic Nucleoside Monophosphates in Aphanizomenon flos-aquae: nuclear magnetic resonance and mass spectrometry 193
Biostimulants derived from organic urban wastes and biomasses: An innovative approach 191
Erratum: Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase (ACS Omega (2022) 7:20 (17083-17097) DOI: 10.1021/acsomega.2c00507) 179
α‐Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML 175
Double-ion doped mesoporous glasses: Studies on stability, antibacterial and antioxidant properties, and bioactivity 174
Synthetic approach to novel NMP/ALK inhibitors 174
Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow 171
Evaluation of the behaviour of hydrogels containing mesoporous glasses doped with cerium and loaded with polyphenols 169
Extraction, purification and in vitro assessment of the antioxidant and anti-inflammatory activity of policosanols from non-psychoactive Cannabis sativa L. 168
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 168
Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis 166
endo-1-Phenylborneol as a novel, alternative chiral auxiliary for the aza-Diels-Alder reaction 164
NON CANONICAL CYCLIC NUCLEOTIDES MONOPHOSPHATES IN APHANIZOMENON FLOS-AQUAE: NUCLEAR MAGNETIC RESONANCE AND MASS SPECTROMETRY 163
Rational design of inhibitors of the anaplastic lymphoma kinase 161
LYSYL OXIDASE INHIBITORS 155
Dual loaded Ce-MBGs with bioactivity, antioxidant and antibacterial properties 152
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 148
Novel ligands from direct benzylic functionalisation of tris(2-pyridylmethyl)amine 147
Preparation of 1-​(5-​tert-​butyl-​2-​aryl-​pyrazol-​3-​yl)​-​3-​[2-​fluoro-​4-​[(3-​oxo-​4H-​pyrido[2,​3-​b]​pyrazin-​8-​yl)​oxy]​phenyl]​urea derivatives as RAF inhibitors for treating cancer 140
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers 137
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 132
Erratum: Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (Cancer Cell (2015) 27(1) (85–96) (S1535610814004577) (10.1016/j.ccell.2014.11.006)) 125
Long-term durability of discarded cork-based composites obtained by geopolymerization 120
Polyphosphate coacervate gels for manufacturing of manganese loaded glass powders and fibres: structural, cytocompatibility and surface bioactivity study 118
Corrections to pyridoimidazolones as novel potent inhibitors of v-raf murine sarcoma viral oncogene homologue B1 (BRAF) (Journal of Medicinal Chemistry (2009) 52, (2255-2256) DOI: 10.1021/jm801509w) 116
PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H PYRIDO2,3-B PYRAZIN-3-ONE DERIVATIVES 107
Erratum: Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma (Journal of Investigative Dermatology (2013) 133 (274-276) DOI: 10.1038/jid.2012.268;0 104
Dual-functional cerium-containing mesoporous bioactive glasses for drug delivery 103
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 101
Enhanced bone regeneration with cerium-doped bioactive glasses: In vitro and in vivo study 100
Targeting monocarboxylate transporter 1 with a copper-chelating coumarin-based bioconjugate: Synthesis and characterization 91
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 91
Gelatin/Cerium-Doped Bioactive Glass Composites for Enhancing Cellular Functions of Human Mesenchymal Stem Cells (hBMSCs) 89
Materiale fotoassorbente ad ampio spettro, procedimento per la sua preparazione ed usi relativi 74
Negative Allosteric Modulators of A2AR: A New Weapon for Cancer Immunotherapy? 70
Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia 67
Totale 23.425
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.632
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.632
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.666 95 210 201 58 73 89 99 82 188 96 288 187
2022/20231.967 245 218 134 187 258 249 71 176 246 46 76 61
2023/20241.625 52 94 110 97 514 43 278 178 43 48 52 116
2024/20254.053 126 43 125 203 806 566 214 319 564 224 398 465
2025/20268.274 425 326 694 901 1.077 999 887 422 736 765 634 408
2026/2027267 267 0 0 0 0 0 0 0 0 0 0 0
Totale 23.478